|
1）Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001; 344: 732-8
|
|
|
|
2）Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol. 2012; 22: 1-14
|
|
|
|
|
3）IgG4関連全身硬化性疾患の診断法の確立と治療方法の開発に関する研究班・新規疾患，IgG4関連多臓器リンパ増殖性疾患（IgG4+MOLPS）の確立のための研究班．IgG4関連疾患包括診断基準2011．日本内科学会雑誌．2012; 101: 795-804
|
|
|
|
|
|
4）Stone J, Khosroshahi A, Deshpande V, et al. IgG4-Related Disease: recommendations for the nomenclature of this condition and its individual organ system manifestations. Arthritis Rheum. 2012; 264: 3061-7
|
|
|
|
|
|
5）Deshpande V, Zen Y, John KC, et al. Consensus Statement on the Pathology of IgG4-related disease. Modern Pathology. 2012; 5: 1181-92
|
|
|
|
|
|
6）Okazaki K, Uchida K, Koyabu M, et al. Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease. J Gastroenterol. 2011; 46: 277-88
|
|
|
|
|
|
7）日本膵臓学会・厚生労働省難治性膵疾患調査研究班．自己免疫性膵炎診療ガイドライン2013．膵臓．2013; 28: 715-84
|
|
|
|
|
|
8）Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995; 40: 1561-8
|
|
|
|
|
|
9）Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003; 38: 982-4
|
|
|
|
|
|
10）Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol. 2006; 41: 613-25
|
|
|
|
|
|
11）Yamamoto M, Takahasgi H, Ohara M, et al. A new conceptualization for Mikuliczʼs disease as an IgG4-related plasmacytic disease. Mod Rheumatol. 2006; 16: 335-40
|
|
|
|
|
|
12）Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multi-organ lymphoproliferative syndrome: Analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis. 2009; 68: 1310-5
|
|
|
|
|
|
13）岡崎和一，住本貴美，光山俊行，他．自己免疫性膵炎からみたIgG4関連疾患と免疫異常．Jpn J Clin Immunol. 2014; 37: 11-8
|
|
|
|
|
|
14）Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012; 18: 1028-40
|
|
|
|
|
|
15）Wallace ZS, Mattoo H, Carruthers M, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2014 May 9. doi: 10.1136/annrheumdis-2014-205233
|
|
|
|
|
|
16）Mattoo H, Mahajan VS, Della-Torre E, et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-relateddisease. J Allergy Clin Immunol. 2014; 134: 679-87. doi: 10. 1016/j. jaci. 2014. 03. 034
|
|
|
|
|
|
17）Della-Torre E, Feeney E, Deshpande V, et al. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. Ann Rheum Dis. 2014 Aug 20. pii: annrheumdis-2014-205799. doi: 10.1136/annrheumdis-2014-205799
|
|
|
|
|
|
18）Sato Y, Kojima M, Takata K, et al. Multicentric Castleman's disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases. J Clin Pathol. 2010; 63: 1084-9
|
|
|
|
|
|
19）Ohara H, Okazaki K, Tsubouchi H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2012; 19: 536-42
|
|
|
|
|
|
20）Shimosegawa T, Chari ST, Frulloni L, et al. International Consensus Diagnostic Criteria for Autoimmune Pancreatitis: Guidelines of the International Association of Pancreatology. Pancreas. 2011; 40: 352-58
|
|
|
|
|